• 3 split doses (20%, 30% and 50% respectively) of cells over a week, and first signs of efficacy appeared as early as 10 days after the initial injection.
• 33/35 (94%) had a remission within 2 months of receiving the CAR T cells; 1 had progression after 3 month PR
• Of 19 more than 4 months: 14 Complete remission + 5 Partial remission
• Of 5 followed 12 to 14 months so far, and all have no detectable cancer cells in their bone marrow.
• CRS occurred in 85% of the patients, but it was temporary and most patients had mild and manageable symptoms. Two patients had severe CRS but recovered. No patients had neurologic side effects.
• The researchers plan to keep adding patients to this study until they reach 100 total patients.
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Overview
ASCO Updates
• The hottest new thing: BCMA CAR-T (4) Either (2) + (3), OR (2) + (4) *CRAB criteria: (1) Serum calcium > 11 mg/dL or > 1 mg/dL above ULN, (2) renal insufficiency (serum Cr > 2 mg/dL or Cr Cl < 40 mL/min), (3) anemia (hemoglobin > 2 g/dL below the LLN, or < 10 g/dL), and (4) bone lesions (one or more osteolytic lesions revealed by skeletal radiography, CT, or PET) ** Myeloma defining events:
(1) clonal bone marrow plasma cell % ≥60 (2) involved to uninvolved serum free light chain ratio ≥ 100 (3) > 1 focal lesions (each ≥ 5 mm in size) on MRI 
Comparison of high risk SMM at various institutions
Conclusions
• The combination of Elo plus RVD was associated with a level of overall response similar to prior studies of RVD in newly diagnosed MM
• A higher than expected number of patients (6/40, 15%) discontinued therapy within the first four cycles of treatment due to adverse events
• Infection occurred in 50% of patients overall, including one grade 5 sepsis, one grade 4 sepsis, and four patients with grade > 3 lung infection
• The high rate of overall response, VGPR or better, and CR + nCR among pts who received at least 4 cycles of therapy is promising 
• RVD remains the standard of care
• …for now
• IMID / PI-containing triplets outperform triplets containing an IMID or PI with a conventional agent
• Increased high quality response rates • Impact on PFS and OS to be determined
• RVD-Elo and KRD-Dara appear promising
• More mature clinical efficacy data from ongoing and planned randomized studies needed • The addition of mAbs to IMID / PI -based therapy is well tolerated but not without risk
• Infection risk appears increased with the use of elo and dara in combination therapy
• Financial toxicity / healthcare economics are important endpoints
• Must weigh short-and long-term costs of care
• Does adding dara to induction allow a shorter duration of induction, omission of consolidation or discontinuation of lenalidomide maintenance? • What is the impact of the mAbs on treatment-and myeloma-related morbidity?
Overview
ASCO Updates
• The hottest new thing: BCMA CAR-T 
Introduction
• Osteolytic bone disease and renal dysfunction are the most frequent complications of multiple myeloma, presenting in up to 90% and 60% patients respectively.
• Denosumab is a human monoclonal antibody that targets RANKL, a key driver of osteoclast-mediated osteolysis, which in turn increases the risk of skeletal-related events (SREs), morbidity, and mortality.
• Denosumab can be administered regardless of renal function and does not need to be dose adjusted, unlike bisphosphonates.
• This international, phase 3, randomized, double-blind study evaluates the efficacy and safety of denosumab compared with zoledronic acid in newly diagnosed multiple myeloma patients and represents the largest international phase 3 trial ever conducted in multiple myeloma, with 1718 patients enrolled from 259 sites and 29 countries.
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Study Design
*No SC dose adjustments were required. † Per protocol and Zometa® label, IV product was dose adjusted for baseline creatinine clearance and subsequent dose intervals were determined by serum creatinine levels.
IMiDs Immunomodulatory drugs; ISS International staging system; IV intravenous; PBSC peripheral blood stem cell; SC subcutaneous; Q4W every four weeks 
Results
• This study successfully demonstrated that denosumab met the primary endpoint of noninferiority to zoledronic for time to first skeletal-related events (HR [95% CI] = 0.98 [0.85, 1.14], P = 0.01); superiority was not significant.
• The difference in overall survival (HR [95% CI] = 0.90 [0.70, 1.16], P = 0.41) was not significant. However, there were limited numbers of deaths on the study.
• Progression-free survival for denosumab was numerically longer (10.7 months) compared to zoledronic acid, with a HR (95% CI) = 0.82 (0.68, 0.99), descriptive P = 0.036. 
Results: Safety Events of Interest
• There were significantly lower incidences of adverse events potentially related to renal toxicity with denosumab therapy compared to zoledronic acid, particularly in those patients with baseline CrCl ≤60mL/minute
• The incidence of hypocalcemia, with the majority of events either grade 1 or 2, was greater for denosumab compared to zoledronic acid; there were no grade 5 events 
Q&A Session
Ask a question by phone:
• Press star (*) then the number 1 on your keypad.
Ask a question by web:
• Click "Ask a question"
• Type your question • Click "Submit"
Due to time constraints, we can only take one question per person.
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